Acer Therapeutics shares are trading higher after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer stockholders of up to $91 million.
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics has announced its plans to acquire Acer Therapeutics. The deal could potentially value Acer at up to $91 million.

August 31, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acer Therapeutics' shares are trading higher following the announcement of its acquisition by Zevra Therapeutics. The deal could potentially value Acer at up to $91 million.
The acquisition announcement by Zevra Therapeutics has led to a rise in Acer Therapeutics' share price. The potential valuation of Acer at up to $91 million indicates a positive outlook for the company's shareholders.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100